- Home
- AVNS vs ETNB Comparison
AVNS vs ETNB Comparison
Compare AVNS & ETNB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AVNS
- ETNB
- Stock Information
- Founded
- AVNS 2014
- ETNB 2018
- Country
- AVNS United States
- ETNB United States
- Employees
- AVNS N/A
- ETNB N/A
- Industry
- AVNS Industrial Specialties
- ETNB Biotechnology: Pharmaceutical Preparations
- Sector
- AVNS Health Care
- ETNB Health Care
- Exchange
- AVNS Nasdaq
- ETNB Nasdaq
- Market Cap
- AVNS 731.6M
- ETNB 773.7M
- IPO Year
- AVNS N/A
- ETNB 2019
- Fundamental
- Price
- AVNS $17.30
- ETNB $10.75
- Analyst Decision
- AVNS Hold
- ETNB Strong Buy
- Analyst Count
- AVNS 1
- ETNB 9
- Target Price
- AVNS N/A
- ETNB $31.43
- AVG Volume (30 Days)
- AVNS 683.9K
- ETNB 3.5M
- Earning Date
- AVNS 02-18-2025
- ETNB 02-27-2025
- Dividend Yield
- AVNS N/A
- ETNB N/A
- EPS Growth
- AVNS N/A
- ETNB N/A
- EPS
- AVNS 0.34
- ETNB N/A
- Revenue
- AVNS $681,500,000.00
- ETNB N/A
- Revenue This Year
- AVNS $3.84
- ETNB N/A
- Revenue Next Year
- AVNS $4.37
- ETNB N/A
- P/E Ratio
- AVNS $50.79
- ETNB N/A
- Revenue Growth
- AVNS N/A
- ETNB N/A
- 52 Week Low
- AVNS $14.98
- ETNB $5.99
- 52 Week High
- AVNS $25.36
- ETNB $16.63
- Technical
- Relative Strength Index (RSI)
- AVNS 52.22
- ETNB 74.66
- Support Level
- AVNS $15.54
- ETNB $9.16
- Resistance Level
- AVNS $17.69
- ETNB $9.90
- Average True Range (ATR)
- AVNS 0.53
- ETNB 0.83
- MACD
- AVNS 0.24
- ETNB 0.41
- Stochastic Oscillator
- AVNS 58.68
- ETNB 82.37
About AVNS Avanos Medical Inc.
Avanos Medical Inc is a United States-based company that develops and sells medical devices and related services globally. Its operating and reportable segment provides medical device products to healthcare providers and patients. The company has now changed two franchises: has combined Chronic Care and Pain Management franchises into a single commercial organization focused on the Digestive Health and Pain Management and Recovery product categories that generate its revenue from its Chronic Care franchise and in North America.
About ETNB 89bio Inc.
89bio Inc is a United States-based clinical-stage biopharmaceutical company focused on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its product candidate, pegozafermin (previously BIO89-100), a specifically engineered glycoPEGylated analog of fibroblast growth factor 21 (FGF21), is currently being developed for the treatment of nonalcoholic steatohepatitis (NASH) and for the treatment of severe hypertriglyceridemia (SHTG).